ArticleEuropean journal of nuclear medicine and molecular imaging2016

The case for combined chemotherapy-peptide receptor radionuclide therapy (chemo-PRRT) strategy in metastatic neuroendocrine tumor: predicting and looking at the possible case scenarios.

Sandip Basu et al.PubMed ↗Publisher ↗

No numbers read from the abstract.